Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 5/2013

01-08-2013

De follow-up na chirurgische behandeling van het gelokaliseerde niercelcarcinoom: een vragenlijst onder Nederlandse urologen

De follow-up na chirurgische behandeling van het gelokaliseerde niercelcarcinoom

Auteurs: drs. T.J. van Oostenbrugge, dr. S.G.C. Kroeze, prof. dr. J.L.H.R. Bosch, dr. H.H.E. van Melick

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 5/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Inleiding:

Momenteel bestaat er geen consensus over de followupstrategie na de chirurgische behandeling van een gelokaliseerd niercelcarcinoom (NCC). Het doel van deze studie is inzicht te krijgen in de klinische toepassing en de persoonlijke visie van Nederlandse urologen over de follow-upstrategieën bij NCC.

Materiaal:

Een anonieme enquête is verzonden naar alle Nederlandse urologen. Vragen betroffen enkele karakteristieken van de uroloog in kwestie, het huidige follow-upbeleid dat is gevolgd door deze uroloog en de persoonlijke mening over het nut en de toekomst van follow-up bij NCC. De uitkomsten zijn gekwantificeerd en vergeleken.

Resultaten:

Er reageerden 154 urologen (41%). 86% van de respondenten gebruikt een richtlijn, de helft volgt deze richtlijn exact. De meest gebruikte richtlijnen zijn die van de EAU (27%) en de VIKC/NVU (46%), of een combinatie van beide (14%). De voornaamste reden voor follow-up is het vroeg ontdekken en behandelen van recidieven (64%). 42% van de respondenten is van mening dat het vroeg behandelen van metastasen de overleving verbetert en 52% denkt zo over het vroeg behandelen van lokale recidieven. Een meerderheid (68%) vindt dat de follow-upstrategie gestandaardiseerd zou moeten worden in Nederland; 67% denkt dat deze strategie zou moeten worden aangepast aan het risicoprofiel van de tumor.

Conclusie:

De meerderheid van de urologen is van mening dat er 1 gestandaardiseerde follow-uprichtlijn in Nederland zou moeten zijn, gebaseerd op het risicoprofiel van de tumor.
Literatuur
1.
go back to reference Lightfoot N, Conlon M, Kreiger N, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol. 2000;37:521–7.PubMedCrossRef Lightfoot N, Conlon M, Kreiger N, et al. Impact of noninvasive imaging on increased incidental detection of renal cell carcinoma. Eur Urol. 2000;37:521–7.PubMedCrossRef
2.
go back to reference Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.PubMedCrossRef Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97:1663–71.PubMedCrossRef
3.
go back to reference Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316–22.PubMedCrossRef Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004;22:3316–22.PubMedCrossRef
4.
go back to reference Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010;57:102–9.PubMedCrossRef Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010;57:102–9.PubMedCrossRef
5.
go back to reference Antonelli A, Cozzoli A, Zani D, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int. 2007;99:296–300.PubMedCrossRef Antonelli A, Cozzoli A, Zani D, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int. 2007;99:296–300.PubMedCrossRef
6.
go back to reference Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466-72; discussion 72; quiz 801.PubMedCrossRef Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol. 2005;174:466-72; discussion 72; quiz 801.PubMedCrossRef
7.
go back to reference Ganz PA, Hahn EE. Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol. 2008;26:759–67.PubMedCrossRef Ganz PA, Hahn EE. Implementing a survivorship care plan for patients with breast cancer. J Clin Oncol. 2008;26:759–67.PubMedCrossRef
8.
go back to reference Khatcheressian J, Swainey C. Breast cancer follow-up in the adjuvant setting. Curr Oncol Rep. 2008;10:38–46.PubMedCrossRef Khatcheressian J, Swainey C. Breast cancer follow-up in the adjuvant setting. Curr Oncol Rep. 2008;10:38–46.PubMedCrossRef
9.
go back to reference Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.PubMedCrossRef Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.PubMedCrossRef
11.
go back to reference Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–57.PubMed Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649–57.PubMed
12.
go back to reference Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–400.PubMedCrossRef Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168:2395–400.PubMedCrossRef
13.
go back to reference Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol. 2009;181:506–11.PubMedCrossRef Scoll BJ, Wong YN, Egleston BL, et al. Age, tumor size and relative survival of patients with localized renal cell carcinoma: a surveillance, epidemiology and end results analysis. J Urol. 2009;181:506–11.PubMedCrossRef
14.
go back to reference Siddiqui SA, Frank I, Cheville JC, et al. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009;104:778–85.PubMedCrossRef Siddiqui SA, Frank I, Cheville JC, et al. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int. 2009;104:778–85.PubMedCrossRef
15.
go back to reference Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008;179:857–61.PubMedCrossRef Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, et al. Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol. 2008;179:857–61.PubMedCrossRef
16.
go back to reference Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol. 2007;51:1490-500;discussion 501. Skolarikos A, Alivizatos G, Laguna P, et al. A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol. 2007;51:1490-500;discussion 501.
17.
go back to reference Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell Carcinoma. Urology. 2011. Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell Carcinoma. Urology. 2011.
18.
19.
go back to reference Donnelly P, Hiller L, Bathers S, et al. Questioning specialists’ attitudes to breast cancer follow-up in primary care. Ann Oncol. 2007;18:1467–76.PubMedCrossRef Donnelly P, Hiller L, Bathers S, et al. Questioning specialists’ attitudes to breast cancer follow-up in primary care. Ann Oncol. 2007;18:1467–76.PubMedCrossRef
20.
go back to reference Baravelli C, Krishnasamy M, Pezaro C, et al. The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up. J Cancer Surviv. 2009;3:99–108.PubMedCrossRef Baravelli C, Krishnasamy M, Pezaro C, et al. The views of bowel cancer survivors and health care professionals regarding survivorship care plans and post treatment follow up. J Cancer Surviv. 2009;3:99–108.PubMedCrossRef
21.
go back to reference Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59:135–41.PubMedCrossRef Sun M, Thuret R, Abdollah F, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59:135–41.PubMedCrossRef
22.
go back to reference Adamy A, Chong KT, Chade D, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011;185:433–8.PubMedCrossRef Adamy A, Chong KT, Chade D, et al. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol. 2011;185:433–8.PubMedCrossRef
23.
go back to reference Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405–11.PubMedCrossRef Ljungberg B, Alamdari FI, Rasmuson T, et al. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int. 1999;84:405–11.PubMedCrossRef
24.
go back to reference Stephenson AJ, Russo P, Kaplinsky R, et al. Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol. 2004;171:1474–7.PubMedCrossRef Stephenson AJ, Russo P, Kaplinsky R, et al. Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol. 2004;171:1474–7.PubMedCrossRef
25.
go back to reference Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48:77-81;discussion -2.PubMedCrossRef Hofmann HS, Neef H, Krohe K, et al. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol. 2005;48:77-81;discussion -2.PubMedCrossRef
26.
go back to reference Umbreit EC, Shimko MS, Childs MA, et al. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2011. Umbreit EC, Shimko MS, Childs MA, et al. Metastatic potential of a renal mass according to original tumour size at presentation. BJU Int. 2011.
27.
go back to reference Grunfeld E. Optimizing follow-up after breast cancer treatment. Curr Opin Obstet Gynecol. 2009;21:92–6.PubMedCrossRef Grunfeld E. Optimizing follow-up after breast cancer treatment. Curr Opin Obstet Gynecol. 2009;21:92–6.PubMedCrossRef
29.
go back to reference Kutikov A, Egleston BL, Wong YN, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28:311–7.PubMedCrossRef Kutikov A, Egleston BL, Wong YN, et al. Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol. 2010;28:311–7.PubMedCrossRef
Metagegevens
Titel
De follow-up na chirurgische behandeling van het gelokaliseerde niercelcarcinoom: een vragenlijst onder Nederlandse urologen
De follow-up na chirurgische behandeling van het gelokaliseerde niercelcarcinoom
Auteurs
drs. T.J. van Oostenbrugge
dr. S.G.C. Kroeze
prof. dr. J.L.H.R. Bosch
dr. H.H.E. van Melick
Publicatiedatum
01-08-2013
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 5/2013
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-013-0069-x

Andere artikelen Uitgave 5/2013

Tijdschrift voor Urologie 5/2013 Naar de uitgave

EditorialNotes

Editorial